What is Pharmacogenomics?

Pharmacogenomics (PGx) is the study of how genetic variations influence the way an individual responds to medications.

PGx is now enabling doctors to test for specific genetic changes to predict whether a patient may have a normal response, a poor response, or a higher risk of side effects before prescribing a specific medication.

Clinical Support
Pharmacogenomic Testing

Our clinical team is here to support you and answer all your questions on either individual results or how to best interpret the report.

Our dedicated pharmacogenomics specialist team includes clinical geneticists, clinical pharmacologists, molecular geneticists and pharmacists.

Printable Resources

To support the conversation with your patient we have a Doctor’s Overview, Patient Information and a Substrate Card covering all the medications that we provide results for. These documents can be used for your reference.

Doctor Overview
Doctor’s Overview
Patient Information
Patient Education
Australian Substrate Card
Substrate Card

Please contact our customer service team for access to our training resources.

Request Sample Report

Registered doctors can request a sample myDNA Medications Report.

Pharmacogenomics has Long Term Healthcare Benefits

Reduce the risk of adverse drug reactions
Reduce trial-and-error when prescribing
Offer a personalised healthcare service
Results have a lifetime relevance
Reduce wasted cost on ineffective medication
Fast-track treatment goals

What do we offer?

The myDNA Medication tests use PGx to identify variations in a number of genes that influence responses to medications and healthcare treatments.

We concentrate on the genes encoding the metabolising enzymes (i.e. CYP450 enzymes) which are found mainly in the liver and the gut wall. These genetic variations predict the level of enzyme activity which in turn results in increased or decreased plasma concentrations and drug exposure.

Increased plasma concentrations, due to reduced enzyme activity, can lead to adverse effects. Reduced plasma concentrations, due to increased enzyme activity, can lead to poor therapeutic response.

We offer a Multiple Category Medication Test, which covers multiple medication categories (currently in excess of over 80 medications).

Our Mental Health Medication Test is available as a single category report.

a icon of a head with a swirl to represent mental health
Mental Health
a icon of a lightning bolt to represent pain
Pain
a icon of a ribbon to represent oncology (cancer)
Oncology
a icon of a stomach to represent gastrointestinal
Gastrointestinal
a icon of a heart to represent Cardiovascular
Cardiovascular

Reduce trial-and-error

a percentage that says 'There is an 88%'
Likelihood

of experiencing side effects if taking 5+ medications1.

a percentage that say 'Up to 65%'
Of patients

with depression don’t have complete remission of their illness when initially treated with antidepressants2.

a diagram showing 1 in 10 people
1 in 10 people

May process certain medications too slowly, increasing their risk of side effects3.

a diagram showing 1 in 3 people
1 in 3 people

May process certain medications too quickly, increasing their risk of treatment failure3.

Patients most likely to benefit from our insights:

Those experiencing side effects to specific medications

Anyone not responding to specific medications

Patients requiring doses of medications outside the recommended range

Patients planning to start on a new medication covered by the myDNA test

Anyone taking multiple medications

  1. Bourgeois FT, Shannon MW, Valim C, et al. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19:901–10
  2. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. NEnglJ Med 2006; 354: 1231–1242
  3. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44.

PGx Healthcare in practice

Customer success stories

PGx is in our DNA

black and white photo of myDNA Co-founder Associate Professor Les Sheffield

Associate Professor Les Sheffield

Clinical Geneticist & myDNA Co-Founder

Since the 1980s Professor Sheffield has been involved in the design and development of genetic tests. As a Clinical Geneticist, he has authored more than 100 scientific publications. In 2007 he founded myDNA to assist in more informed prescribing of medications. He continues to drive the development of new healthcare services as Medical Director.

It is estimated that the Australian healthcare system would save over $1 billion per year by implementing pharmacogenetic testing and thereby avoiding many adverse drug reactions.1 Further substantial savings would accrue from avoiding wastage of drugs that were predicted to be ineffective for a patient, and from improved health outcomes for patients.2

  1. Australian Centre for Health Research. Improving the Quality Use of Medicines in Australia. [Internet] 2008 [cited 2022 July 28]; Available from: https://globalaccesspartners.org/Improving_the_Quality_Use_of_Medicines_in_Australia.pdf
  2. The Royal College of Pathologies of Australia. Utilisation of pharmacogenetics in healthcare. [Internet] 2018 [cited 2022 July 28]; Available from: https://www.rcpa.edu.au/Library/College-Policies/Position-Statements/Utilisation-of-pharmacogenetics-in-healthcare

Evidence behind pharmacogenomic testing

We reference the guidelines of the Royal Dutch Pharmacists Association, Pharmacogenetics Pharmacogenomics Working Group & the Clinical Pharmacogenetics Implementation Consortium (CPIC), which have been most recently published.

The following publications contain significant evidence for gene-drug associations of which dosage adjustments have been recommended.

  1. CPIC Guideline for CYP2D6 and CYP2C19 genotypes and dosing of Tricyclic Antidepressants
  2. CPIC Guideline for CYP2D6 and CYP2C19 genotypes and dosing of Selective Serotonin Reuptake Inhibitors (SSRIs)
  3. Dutch Pharmacogenetics Working Group guidelines which include a number of antidepressant and antipsychotic medications

Our scientific partner network

Healius Logo
BC Platforms Logo
Illumina Logo
Dorevitch Pathology Logo
Laverty Pathology Logo
Western Diagnostic Pathology Logo
Genomic Diagnostics Logo
QML Pathology Logo
TML Pathology Logo
Abbott Pathology Logo
Australian Clinical Labs Logo
Melbourne Health Logo
Peter MacCullum Logo
Bumrungrad Logo
British Columbia Pharmacy Association Logo
Royal Children's Hospital Melbourne Logo

A growing global network with the flexibility to scale and customise accordingly

AUSTRALIA | NEW ZEALAND | USA | CANADA | UK | INDONESIA | SINGAPORE | THAILAND | PHILIPPINES | VIETNAM | BANGLADESH

Trusted accreditation on a global scale

NATA Logo
Department of Health Therapeutic Goods Administration Logo
FDA Logo
Health Canada Logo
Medsafe Logo
Global Alliance for Genomics & Health Logo

Your data under lock and key

Your DNA sample and data remain your property, are stored on secure encrypted services, can be destroyed anytime at your request, and will never be shared without your consent.

Our analysis is limited to the DNA markers we report on. Your results won’t include diseases, can’t be used to identify you, nor will they have any bearing towards insurance policies.

Enquire about genomic reporting for your business

Leave your details below and our partnership team will be in touch.

Popular Searches ...Hide Popular Searches